Eli Lilly And Company (LLY): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Eli Lilly and Company ( LLY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.4%. By the end of trading, Eli Lilly and Company rose $2.84 (5.1%) to $58.09 on heavy volume. Throughout the day, 15,991,072 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5,077,000 shares. The stock ranged in a price between $56.55-$58.20 after having opened the day at $57.30 as compared to the previous trading day's close of $55.25. Other companies within the Drugs industry that increased today were: Chelsea Therapeutics International ( CHTP), up 24.4%, Tianyin Pharmaceutical ( TPI), up 22.2%, China Pharma ( CPHI), up 20.1% and Nanoviricides ( NNVC), up 16.6%.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $61.1 billion and is part of the health care sector. Shares are up 6.3% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 3 analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Prana Biotechnology ( PRAN), down 13.3%, Geron Corporation ( GERN), down 6.9%, Amyris ( AMRS), down 6.8% and Portola Pharmaceuticals ( PTLA), down 6.4% , were all laggards within the drugs industry with Pfizer ( PFE) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet